RecruitingPHASE1, PHASE2NCT07172802

A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Studying Squamous cell carcinoma of pancreas

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: GI Innovation, Inc.
Intervention: GI-108(drug)
Enrollment: 76 target
Eligibility: 18 years · All sexes
Timeline: 2025 – 2027

Study locations (3)

Yonsei University Health System, Severance Hospital, Seoul, South Korea
Asan Medical Center, Seoul, South Korea
Samsung Medical Center, Seoul, South Korea

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07172802 on ClinicalTrials.gov

Other trials for Squamous cell carcinoma of pancreas

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2NCT05945823
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.

See all trials for Squamous cell carcinoma of pancreas →

← Back to all trials